Oct 28, 2026 earnings call — BLA filing and Fareva remediation
DBV filed a BLA for children 4-through-7 and had USD 165.7 million cash, funding operations into the third quarter of 2027.
Revenue $0.0B (est $0.0B) · EPS $-0.70 (est $-0.29)
Key quotes
"The highlight of the quarter was the filing of our BLA in 4 to 7-year olds."
"The responsibility for satisfactory remediation of the findings cited in the Warning Letter resides entirely with the company that received it, in this case, Fareva Amboise."
"We'll continue our dialogue with the FDA over the next few months and expect to submit a toddler BLA in 2027."
Analyst Q&A 9
Fareva reports and FDA reinspection timing
Q (Kristen Kluska · Cantor Fitzgerald): She asked if Fareva shares its monthly reports and whether the FDA reinspection has been scheduled and when the public will know the outcome.
A: Management said Fareva shares many monthly reports but not everything because they make many products for many customers; they are satisfied with what they see. They said the FDA visit has not been scheduled yet and it would be premature; they will share timing with investors as steps are crossed.
"To your second question, the FDA visit has not been scheduled yet, but it would be a bit premature to do that." — Daniel Tassé
who answers toddler and remediation questions
Q (Sushila Hernandez · VLK): She asked if Fareva is tracking its detailed plan and if there is sufficient time for remediation before the pre-approval inspection, and also asked about COMFORT toddler data and toddler BLA submission timing.
A: Management said they would have Pharis answer the toddler questions and then address the remediation question afterwards. Daniel handed the toddler questions to Pharis and said they would answer the remediation process afterward.
"The last two questions on toddlers, I'll have Pharis answer them, while we'll answer your question about the remediation process afterwards." — Daniel Tassé
remediation progress and inspection buffer
Q (Pharis Mohideen · VLK): The analyst asked whether Fareva is on track with its remediation plan and whether there is sufficient buffer time before the pre-approval inspection; also asked about COMFORT toddler timing and BLA sequencing.
A: Pharis said COMFORT Toddler recruitment ended in the second quarter and it is a supplemental 6-month safety study; he emphasized coordination with FDA to avoid the 1-to-3 filing creating a bottleneck for the 4-to-7 BLA and noted they could legally submit but prefer to cooperate with the Agency. Kevin said they work daily with Fareva and consultants and are quite comfortable with Fareva's remediation progress and with the buffer for the reinspection relative to the PAI.
"So as I mentioned, we work very, very closely with Fareva, as well as a number of consultants on a daily basis, and we're quite comfortable with the progress that they're making in terms of the remediation." — Kevin Malobisky
warning letter details and second supplier
Q (Jonathan Wolleben · Citizens): He asked what the Warning Letter detailed and which remediation activities are ongoing, and whether the company is considering a second manufacturer for redundancy.
A: Management said they need a second manufacturing unit to support longer-term forecasts but building a new facility takes about 3 years, so it's not a short-term backup to Fareva; their plan is to remediate and launch from Fareva's capacity. Kevin said the FDA inspection that led to the Warning Letter focused on a veterinary product and an aseptic manufacturing process at the site, and remediation is looking site-wide even though the original observation was separate from VIASKIN Peanut.
"So the focus of the FDA inspection that led to the Warning Letter, as Daniel had mentioned earlier, was on a veterinarian product and an aseptic manufacturing process at their site." — Kevin Malobisky
priority review, voucher, and launch prep
Q (Yatin Suneja · Guggenheim Partners): He asked if the company still expects a Priority Review and if there is enough time under that timeline; he also asked about eligibility for a Priority Review voucher and how they would think about monetizing it, plus commercial launch preparations and sales force hiring.
A: Management said they are eligible for Priority Review due to their breakthrough designation, the request has been made, and they are planning on a tight Priority Review timeline. They explained the strict rules for pediatric vouchers likely would not apply to VIASKIN Peanut given the population numbers (250,000 to 300,000 kids), and they described commercial planning: targeting 4,500 allergists with a sales force of 50 to 70 people, parent outreach, payer engagement, and that sales hiring and inventory build come closer to launch after many months of preparation (about 18 months).
"We are eligible for Priority Review given our breakthrough designation." — Daniel Tassé
priority review for 1-to-3 and COMFORT results
Q (Samuel Slutsky · LifeSci Capital): He asked whether breakthrough designation and Priority Review apply to the 1-to-3 age group and what the COMFORT toddlers press release might contain.
A: Management said it is untested whether one breakthrough designation could support two BLAs; 1-to-3 has an accelerated approval pathway that is eligible for Priority Review, but they have no firm answers or commitments from the FDA yet. They said they will press release COMFORT results when available; EPITOPE is the pivotal study and COMFORT is a supplemental safety study that could be provided to the FDA as part of the BLA or as a later safety update.
"To be very clear, I'm sharing with you what our thinking is here. We don't have those answers. We don't have those commitments from the Agency yet." — Daniel Tassé
COMFORT toddler press release content
Q (Pharis Mohideen · LifeSci Capital): He asked whether the COMFORT Toddler announcement will be a simple box-check saying safety is in line with prior studies or whether it will contain more.
A: Pharis said they have about a 2,000-patient database and the product is well characterized, so they do not expect unexpected safety findings. He said the COMFORT study has no primary endpoint and is not powered for a specific outcome, so the press release will likely be a 'check-the-box' announcement noting study completion and exposure numbers met.
inspection readiness and mock inspections
Q (Gavin Clark-Gartner · Evercore): He asked what updates and timelines investors should expect over the next 6–7 months as the review progresses, including mock PAI and when the PAI would be scheduled.
A: Management said February 1 is the date they told the FDA they'd be ready for an inspection, and there will be mock PAI inspections before that. They said regular mock inspections are common, several inspections will verify readiness, and relevant developments may be shared with the market as the dossier progresses.
"February 1 is the date we have shared with the FDA that we'd be ready for an inspection." — Daniel Tassé
payer talks and first-year sales guidance
Q (Theodora Beadle · Goldman Sachs): She asked how far payer discussions have progressed and what early feedback they have, and she asked about first-year sales potential for 4-to-7-year-olds.
A: Management said they will not provide first-year sales guidance now and will present launch details closer to launch when Kevin Trapp will walk investors through the market. They said conversations with payers are relatively limited at this time but account managers are already talking to the big payers; payer work is part of their commercial strategy including health economic arguments and prior authorization planning.
"As far as conversations with payers, I see it obviously to be relatively limited at this point in time." — Daniel Tassé